Press ReleasesBack to Press Releases
Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6
Jan 31, 2022 | PDF Version
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that two abstracts – including an oral presentation on MPS-1 – have been accepted for presentation at the upcoming 18th Annual WORLDSymposium™, being held February 7-11th in San Diego.
Title: “Development of a novel encapsulated non-viral cell-based, BBB-penetrant therapy for MPS I” (also presented as poster #230)
Date/Time: Thursday, February 10th at 1:54 PM EST/10:54 AM PST
LIVE QA Session: Thursday, February 10th at 2:18 PM EST/11:18 AM PST
Title: “Development of a novel encapsulated non-viral cell-based therapy for MPS VI” (poster #231)
Date: Thursday, February 10th
LIVE QA Session: 6:00-8:00 PM EST/3:00-5:00 PM PST
The posters will be available to attendees beginning at 6:00 PM EST/3:00 PM PST on Monday, February 7th on the WORLDSymposium™ virtual platform and will remain open throughout WORLDSymposium™ 2022. Following the presentations, the presentation materials will be made available on the “Presentations” page of the “Science” section of the Sigilon corporate website, www.sigilon.com.
Additionally, please visit Sigilon’s booth in the exhibit hall to learn more about the Company and its commitment to patients and caregivers.
About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or other therapeutic molecules needed by patients living with chronic diseases such as lysosomal diseases and diabetes. The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, which is designed to shield them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. These forward-looking statements address various matters, including the results and potential benefits of our preclinical studies. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, that favorable preclinical results are not predictive of clinical trial results, the FDA or other regulators may request additional preclinical studies or clinical trials beyond those that we currently anticipate, and the risks identified under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended September 30, 2021 and in any subsequent filings with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
SOURCE: Sigilon Therapeutics, Inc.
Robert Windsor, Jr., J.D.
VP, Head of Investor Relations